Beryl Drugs Ltd
Incorporated in 1993, Beryl Drugs Ltd
is in the business of pharmaceuticals manufacturing[1]
- Market Cap ₹ 11.6 Cr.
- Current Price ₹ 22.8
- High / Low ₹ 46.0 / 20.3
- Stock P/E 145
- Book Value ₹ 18.3
- Dividend Yield 0.00 %
- ROCE 11.6 %
- ROE 8.95 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 26.4%
- Company has a low return on equity of 3.66% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
14.42 | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.72 | 20.54 | |
13.50 | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.36 | 18.38 | |
Operating Profit | 0.92 | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.36 | 2.16 |
OPM % | 6.38% | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.83% | 10.52% |
0.12 | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 0.00 | |
Interest | 0.14 | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.55 | 0.58 |
Depreciation | 0.29 | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.24 |
Profit before tax | 0.61 | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.34 |
Tax % | 36.07% | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | |
0.39 | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.08 | |
EPS in Rs | 0.76 | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 0.16 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 16% |
3 Years: | 24% |
TTM: | -32% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | 113% |
TTM: | -93% |
Stock Price CAGR | |
---|---|
10 Years: | -6% |
5 Years: | 40% |
3 Years: | 31% |
1 Year: | -35% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 2% |
3 Years: | 4% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.06 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
Reserves | 1.06 | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.21 |
0.89 | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.54 | |
1.92 | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 3.16 | |
Total Liabilities | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 17.00 |
2.85 | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 7.27 | |
CWIP | 0.00 | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 1.24 | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 |
4.84 | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.73 | |
Total Assets | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 17.00 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.78 | 0.00 | 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.47 | 2.48 | 0.82 | |
-0.70 | 0.00 | 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.52 | -1.30 | -1.08 | |
0.08 | 0.00 | -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.24 | -1.17 | 0.10 | |
Net Cash Flow | 0.16 | 0.00 | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 56.70 | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.54 |
Inventory Days | 30.75 | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | ||
Days Payable | 52.72 | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | ||
Cash Conversion Cycle | 34.73 | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.54 |
Working Capital Days | 35.69 | 75.56 | 84.70 | 105.37 | 120.89 | 105.53 | 43.59 | 82.25 | 120.45 | 154.77 | 71.26 | 94.67 |
ROCE % | 11.59% | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.65% |
Documents
Announcements
- COMPLIANCE CERTIFICATE UNDER REGULATION 40(9) 12 Apr
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
12 Apr - Non-applicability of Annual Secretarial Compliance Report.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Submission of compliance documents for Q1 2025.
- COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED 31ST MARCH, 2025 9 Apr
-
Compliance-57 (5) : intimation after the end of quarter
9 Apr - Regulation 57(5) not applicable for the quarter.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
BDL is mainly engaged in the domestic, institutions, and export supply of bulk drugs, pharmaceuticals, and healthcare products
like I.V. Fluids and Small Volume Injectables.
It manufactures and markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network and provides research and development, contract manufacturing services, and veterinary products.